anonymous
Guest
anonymous
Guest
Over/under on the latest rumors of a buyout being true
Over/under on the latest rumors of a buyout being true
I think this is pretty much spot on at this point.No buyout. 2 reasons. One being nobody wants us with 2 drugs with only 5 years to recoup. Larger players like allergan ate actually divesting.
Secondly, if they lose our blue chip vyvanse and we lose a huge chunk to Roche in market share you may as well flush their little rare disease aspirations down the toilet. If Roche wins in court this summer shire rare disease is "foaked" as Connor mcgregor would say. They will be happy to hold and market their ADHD life preserver. However mydayis will be closer to the 250 mil Wall Street said not the pipe dream Perry and flem had.
No sale. Highly unlikely
Negative. That was a stock pump and dump rumor from 2 days ago. UBS and Jeffries say there are much more attractive targets for Pfizer that the ADHD business lolPfizer buyout coming. Maybe?
Abbvie has their own CNS sales force, we are screwed!Abbvie is back in the hunt. They are growing their CNS/Neuro business. Merry Xmas!
Abbvie is back in the hunt. They are growing their CNS/Neuro business. Merry Xmas!
If there were truly interest in someone buying Shire the stock price would be lots higher. The rumors are just a last ditch effort by our failing CEO to prop up the stock. The Board should be ashamed of itself for letting the company go into the crapper, taking a losing position in sales and R&D in all our key areas - hemophilia, CNS, rare disease and immunology. Lesson is that inferior leaders lead nowhere.If you think Abbvie wants Shire adhd you are truly stupid and now shit about absolutely nothing.
The merger/buyout bull is over trust me. Like Trump or corporate tax rates will be lowest in history. Inversion tax treatment, though had been reduced, has now been eliminated completely. Abbvie huh? You guys are just too funny talking about crap you know nothing about. Shire's Irish address no longer means anything. With all the setback in R&D and the potential for Roche and other taking rare disease business there is no way they can let it go. Abbvie is not buying old business 5 years from generic. Even if they did, the people that are selling Vyvanse would have a short time to recoup and would want all hands on deck. Not sure why you come on here talking crap. You probably are mad about your bonus.
Everyone: Let's stay positive and make 2018 a highly successful sales year. If we see negative posts, contact site monitor for removal. Don't let a few bad apples define our company's image. Thank You and Happy New Year!
Everyone: Let's stay positive and make 2018 a highly successful sales year. If we see negative posts, contact site monitor for removal. Don't let a few bad apples define our company's image. Thank You and Happy New Year!